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Abstract
Aims Multidisciplinary heart failure (HF) clinics are a cornerstone of contemporary HF management. The stent-for-life (SFL)
initiative improves mortality after ST elevation myocardial infarction (STEMI), but its impact in post-STEMI HF is not well
characterized. Here we assessed the impact of SFL among patients referred to a multidisciplinary HF clinic over a 15 year
time period.
Methods and results Between 2001 and 2015, 1921 patients were admitted to our HF clinic. In 2009, Catalonia established the
Codi IAM network, a regional STEMI network that prioritizes primary percutaneous coronary intervention in STEMI. Patients
admitted during the study period were divided into two groups based on admission date: pre-SFL (2001–June 2009; n = 1031)
and post-SFL (July 2009–2015; n = 890). Compared with those in the pre-SFL group, patients admitted in the post-SFL period
had better New York Heart Association (NYHA) functional class (22.1 vs. 38.7 NYHA classes III–IV; P < 0.001) and higher left
ventricular ejection fraction (LVEF) (36.1 ± 19.6 vs. 32.6 ± 13.4; P< 0.001). Among STEMI survivors, 101 (6.7%) pre-SFL patients
and 40 (2%) post-SFL patients (P< 0.001) fulfilled the criteria for HF clinic referral (Killip–Kimball class ≥ 2 during index admission
and/or LVEF of <40%). Furthermore, among patients admitted to the HF clinic, post-STEMI HF with reduced ejection fraction
patients comprised 8.9% of the pre-SFL group and only 4.2% of the post-SFL group (P < 0.001).
Conclusions Among patients treated at our multidisciplinary HF clinic, the adoption of an SFL network has decreased the
prevalence of post-STEMI HF with reduced ejection fraction.
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Introduction
Contemporary management of heart failure (HF) includes
multidisciplinary structured follow-up programmes that
provide patient education, medical treatment optimization,
psychosocial support, and improved access to care.1 Such
strategies are designed to improve outcomes and reportedly
reduce HF-related hospitalization and mortality following
hospital discharge.2 Heart failure programme implementa-
tion necessitates close collaboration between HF practi-
tioners (primarily cardiologists, HF nurses, and general
practitioners) and other experts, including pharmacists,
dieticians, physiotherapists, psychologists, palliative care
providers, and social workers.1 Our institution established a
multidisciplinary HF clinic in 2001.3,4
The prognosis of patients with HF has been profoundly
impacted by advances in drug therapy, devices, and coronary
revascularization—particularly the advent of primary percu-
taneous coronary intervention (p-PCI).1 The stent-for-life
(SFL) initiative is a unique European platform that encourages
cooperation between interventional cardiologists, govern-
ment representatives, industry partners, patient groups, and
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patients to help shape healthcare systems and medical
practices, with the aim of ensuring equal access to life-
saving treatment with p-PCI for the majority of ST elevation
myocardial infarction (STEMI) patients (http://www.
stentforlife.com/). The SFL initiative began in Catalonia in
2009 as the Codi IAM network, which coordinates STEMI
treatment among hospitals with various levels of technology
that are connected by an efficient ambulance service. The
set-up of the Codi IAM network, including the territorial orga-
nization and available resources, has been previously
described.5,6
Our institute is a tertiary university hospital that has the
only critical cardiovascular care unit (CCCU) within a well-
defined geographical area covering ~850 000 inhabitants in
the northern Barcelona Metro Area. In our present study,
we analysed the impact of the SFL initiative, by comparing
clinical characteristics of patients referred to our multidisci-
plinary HF clinic during two time periods: pre-SFL (2001–June
2009) and post-SFL (July 2009–2015).
Patients and methods
For this study, we considered all consecutive ambulatory
patients referred to the structured multidisciplinary HF
clinic of our university hospital between August 2001 and
December 2015. Criteria for referral to the HF clinic
(unchanged over the 15 year period) included HF with at
least one hospitalization and/or reduced left ventricular
ejection fraction (LVEF) of <40% and that have previously
been described in detail.3,4 Most patients were referred
from cardiology and internal medicine departments, with
smaller proportions from the emergency room/short-stay
unit or other hospital departments. All patients were seen
regularly during follow-up visits at the HF clinic, according
to their needs.
This study was performed in compliance with laws
protecting personal data and with the international guide-
lines for clinical investigation from the World Medical
Association’s Declaration of Helsinki.
Statistical analysis
Categorical variables are expressed as percentages. Distribu-
tion normality was assessed with normal Q-to-Q plots.
Continuous variables with normal distributions were
expressed as mean (standard deviation), and those with
non-normal distributions as median (quartiles Q1–Q3).
Differences between the two study groups were assessed
using the χ2 test, Student’s t-test, Mann–Whitney U test,
and Kruskal–Wallis test. Statistical analyses were performed
using SPSS 15 (SPSS, Inc., Chicago, IL). A two-sided P value
of <0.05 was considered significant.
Results
From August 2001 to December 2015, 1921 patients were ad-
mitted to our HF clinic: 1031 pre-SFL and 890 post-SFL. Pa-
tients of both periods showed similar clinical characteristics,
including age (66.7 ± 12 vs. 66.9 ± 13 years; P = 0.72), sex
(71.3% vs. 70.2% men; P = 0.61), and body mass index
(27.5 ± 5.3 vs. 27.5 ± 5.5 kg/m2; P = 0.95).
Compared with HF clinic attendees in the pre-SFL group,
those admitted during the post-SFL period tended to show a
shorter HF duration [6 (2–38) vs. 12 (1–48) months; P = 0.1],
less often had history of previous myocardial infarction
(31.8% vs. 48.3%; P< 0.001), showed a better New York Heart
Association (NYHA) functional class (22.1 vs. 38.7 NYHA classes
III–IV; P < 0.001), and had higher LVEF (36.1 ± 19.6 vs.
32.6 ± 13.4; P < 0.001) (Table 1). The improved LVEF was not
due to patients referred to the HF clinic owing to STEMI (LVEF
31.4 ± 7.1 vs. 31.7 ± 7; P = 0.79) but rather to the lower number
of such patients (see below) and the increase of patients with
other HF aetiologies, such as dilated cardiomyopathy (151 vs.
99) and hypertrophic cardiomyopathy (15 vs. none). Table S1
provides STEMI patients’ characteristics in both study periods.
Applying the 2016 European Society of Cardiology classifica-
tion of HF, we found that the post-SFL group showed a re-
duced proportion of patients with HF with reduced ejection
fraction (HFrEF) and increased proportions of patients with
HF with mid-range or preserved ejection fraction (HFmrEF or
HFpEF, respectively) (P for trend of 0.01). In a multivariable
logistic regression analysis with HFrEF as the dependent vari-
able and significant clinical and treatment confounding factors
[age, sex, previous myocardial infarction, hypertension, isch-
aemic aetiology, NYHA functional classes III–IV, HF duration,
atrial fibrillation/flutter, treatment with implantable cardiac
defibrillator, cardiac resynchronization therapy, beta-blockers,
angiotensin-converting enzyme inhibitor/angiotensin II recep-
tor blocker, ivabradine, and mineralocorticoid receptor
antagonist, and study period (pre-SFL and post-SFL)], we ob-
served that post-SFL period remained significantly associated
with a lower prevalence of HFrEF patients [odds ratio 0.68
(95% confidence interval 0.54–0.87), P < 0.001].
Regarding aetiology, patients in the post-SFL period were
less commonly referred with HF of ischaemic origin (55.6%
vs. 44%; P < 0.001).
Regarding the impact of the SFL initiative, there were 3545
STEMI CCCU admissions during the 15 year period. Table S1
shows clinical data of these CCCU patients in both study pe-
riods. Among 1516 pre-SFL admissions, 516 (34%) were
treated with p-PCI (performed only during office hours).
Among 2029 post-SFL admissions, 1838 (91%) were treated
with p-PCI (performed 24/7). Among STEMI survivors, 101
(6.7%) pre-SFL patients and 40 (2%) post-SFL patients
fulfilled the predefined criteria for referral to the HF clinic
(Killip–Kimball class ≥ 2 during index admission and/or LVEF
of <40%), showing a highly significant reduction between
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the two studied periods (P< 0.001). Furthermore, among pa-
tients admitted to the HF clinic, STEMI patients comprised
9.8% of the pre-SFL group and 4.5% of the post-SFL group
(P < 0.001) (Figure 1), and post-STEMI HFrEF patients com-
prised 8.9% of the pre-SFL group and 4.2% of the post-SFL
group (P < 0.001). In point of fact, irrespective of the STEMI
revascularization procedure, a similar LVEF was found in both
study periods (31.6 ± 7.5 vs. 31.6 ± 6.6; P = 0.97). Indeed, the
key message is the lower number of such patients in the SFL
period, with fewer patients fulfilling the derivation criteria.
Treatment differences in patients referred to the HF clinic
relative to study periodweremainlymineralocorticoid receptor
antagonists, much more used in the second period (Table S2).
Discussion
The SFL initiative has profoundly impacted the development of
regional STEMI networks across Europe.7 In Catalonia, the Codi
IAM network was launched in 2009 and has already notably re-
duced STEMI-driven mortality.6 Early reperfusion also has the
potential to salvage viable myocardium and reduce STEMI-
derived HF. Herein, we report a highly significant ~70% reduc-
tion in the number of STEMI patients with HF requiring care at
an HF clinic based on well-defined referral criteria.
The present data have clinical implications. First, imple-
mentation of the SFL Codi IAM network has led to a lower
frequency of HFrEF of ischaemic origin due to STEMI. During
the post-SFL period, only 4.2% of patients attending our HF
clinic had post-STEMI HFrEF, and this population comprised
2% of all STEMI cases fulfilling the criteria for HF clinic refer-
ral. The classical quote ‘time is myocardium’ remains perti-
nent to reducing STEMI mortality and morbidity. Second,
we identified a trend towards increasing prevalences of
patients with HFmrEF and HFpEF. In essence, HFmrEF largely
resembles HFpEF with the key exceptional characteristic of
involving ischaemia, as in HFrEF.8 Larger prospective random-
ized clinical trials in HFmrEF are required to better under-
stand its pathophysiology and therapeutic needs. Third,
Table 1 Baseline clinical characteristics of patients
Pre-SFL Post-SFL
P value N=1921N=1031 N=890
Age, years 66.7 ± 12.1 66.9 ± 13.3 0.72 1921
Male 735 (71.3) 625 (70.2) 0.89 1921
White 1015 (99.4) 881 (99) 0.35 1921
HF duration, months 12 (1–48) 6 (2–38) 0.16 1921
LVEFa, % 32.6 ± 13.4 36.1 ± 19.6 <0.001 1921
ESC HF classification 0.01 1921
HFrEF 786 (76.2) 617 (66.4)
HFmrEF 127 (12.3) 137 (15.4)
HFpEF 118 (11.4) 136 (15.3)
Ischaemic aetiology 573 (55.6) 392 (44) <0.001
NYHA class III–IV 399 (38.7) 197 (22.1) <0.001 1921
Previous AMI 498 (48.3) 283 (31.8) <0.001 1921
Diabetes 418 (40.5) 393 (44.2) 0.11 1921
Hypertension 615 (59.7) 604 (67.9) <0.001 1921
Anaemiab 447 (46.6) 397 (44.6) 0.62 1859
Renal insufficiencyc 423 (41) 406 (45.6) 0.01 1900
Atrial fibrillation/flutter 206 (20) 225 (25.3) 0.005 1921
LBBB 138 (13.4) 105 (11.8) 0.30 1921
Heart rate 73.5 ± 14.7 69.6 ± 14.6 <0.001 1921
Blood pressure 126.3 ± 46.5 130 ± 34.5 0.05 1921
BMI, kg/m2 27.5 ± 5.3 27.5 ± 5.5 0.95 1904
Treatment 1921
ACEI/ARB 806 (78.2) 610 (68.5) <0.001
Beta-blockers 647 (62.8) 706 (79.3) <0.001
MRA 264 (25.6) 375 (42.1) <0.001
Loop diuretics 788 (76.4) 702 (78.9) 0.20
Digoxin 273 (26.5) 183 (20.6) 0.002
Ivabradine 1 (0.1) 103 (11.6) <0.001
CRT 13 (1.3) 44 (4.9) <0.001
ICD 46 (4.5) 80 (9) <0.001
ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; BMI, body mass
index; CRT, cardiac resynchronization therapy; ESC, European Society of Cardiology; HF, heart failure; HFmrEF, heart failure with mid-
range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, im-
plantable cardiac defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor an-
tagonist; NYHA, New York Heart Association; SFL, stent for life.
aAssessed in almost all patients with two-dimensional echocardiography by Simpson’s method.
bHaemoglobin < 12 g/dL in women and <13 g/dL in men.
cEstimated glomerular renal filtration (Chronic Kidney Disease Epidemiology Collaboration equation) < 60 mL/min/1.73 m2.
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since activation of the SFL Codi IAM network, substantially
more STEMI patients have attended a Codi IAM 24/7 hospital.
However, the majority is Killip–Kimball class < 2 and does not
require follow-up at a dedicated multidisciplinary HF clinic.6
Rehabilitation clinics may be more appropriate for this pa-
tient subgroup. Furthermore, the SFL Codi IAM network has
successfully reduced STEMI-related mortality and morbidity
to date; it is important to remain vigilant and continue active
public awareness campaigns.9
We acknowledge that our present study has several limita-
tions. Owing to its observational, retrospective, and single-
centre nature, this report cannot provide a comprehensive
overview of the magnitude of HF after STEMI. Rather, it re-
flects our experience in a real-life multidisciplinary HF clinic
over a 15 year period during which clinical pathways and re-
ferral geographical areas have remained stable. Moreover, it
is beyond the scope of this study to characterize all factors
that could have potentially impacted HF over the past
15 years. We previously reported in detail the characteristics
of the Codi IAM network6 and of our HF clinic.3,4 The aim of
our present report was to study both initiatives, to illustrate
the changing face of HF in the 21st century. The temporal bias
and the importance of different techniques in different time-
lines during the study period should also be taken into
consideration.
In conclusion, fewer patients with post-STEMI HFrEF have
been referred to our multidisciplinary HF clinic since the
adoption of an SFL network in Catalonia. Notably, STEMI
HFrEF accounted for 8.9% of patients admitted during the
pre-SFL period and only 4.2% in the post-SFL period. Further
comprehensive studies are needed to determine whether
circa post-STEMI HFrEF is declining from HF clinics as a result
of the SFL initiative, as seems to be the case in our HF clinic.
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Figure 1 Yearly distribution of post-ST elevation myocardial infarction (STEMI) patients with heart failure (HF) who attended our HF clinic over
15 years. Note the dramatic reduction in the number of patients after implementation of the stent-for-life (SFL) Codi IAM network.
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